APASL Oncology 2021

“Your Gateway to Oncology in Asia-Pacific Region”

Final Information

Term: December 17-18, 2021
City: Tokyo, Japan (Hybrid Meeting)
Onsite-Venue: The Prince Park Tower Tokyo
President: Mitsuhiro Moriyama, M.D.

Professor and Chairman,
Division of Gastroenterology and Hepatology,
Department of Internal Medicine,
Nihon University School of Medicine
世界中の人々の
より豊かな人生のため、
革新的医薬品に
思いやりを込めて

日本イーライリリーは製薬会社として、
人々がより長く、より健康で、充実した生活を実現できるよう、
がん、糖尿病、筋骨格系疾患、中枢神経系疾患、自己免疫疾患、
成長障害、疼痛などの領域で、日本の医療に貢献しています。

日本イーライリリー株式会社
〒651-0086 神戸市中央区磯上通5-1-28
www.lilly.co.jp
i が描く新たな地平。

アプリオが変わる。i-series が新しい視野を持つ。
最先端技術を搭載し、超音波診断装置に革新をもたらした i-series の誕生から5年。
Aplio i-series は、コアとなるCPU/GPUを刷新し、設計段階で機能検証を行い、
キャノンが培った先進の画像技術、ワークフロー、アプリケーションをより先駆け化しました。
超音波診断における、さまざまな診療領域・診断ニーズをハイレベルなニーズで実現します。
Aplio i-series / Prism Edition の誕生です。

Image Quality
Prism Edition
Application
Work flow

オールインワンの1台をキャノンから
Aplio i-series  Prism Edition
※Ai:Aplio i-seriesの略です。

キャノンメディカルシステムズ株式会社  https://jp.medical.canon

Made For life
APASL Oncology 2021 in Tokyo

“Your Gateway to Oncology in Asia-Pacific Region”

Hybrid Meeting (Onsite-Venue: The Prince Park Tower Tokyo)

December 17-18, 2021

Table of Contents

Welcome Message 2
Invited Guest Speakers / Chairs / Scientific Committee 4
Organizing Committee 5
Conference Information 6
On-Site Venue 7
Instruction for Oral Presentation 8
Instruction for Chairs 9
Instruction for On-Site Poster Presentation 10
Instruction for E-Poster Presentation 11
Awards / Contact 12
Sponsors and Support Organization 14
Program at a Glance 16
Scientific Program 18
On-site Poster Session Program 33
E-Poster Session Program 37
Welcome Message

Dear Colleagues,

It gives us great pleasure to welcome you to the Asian Pacific Association for the Study of the Liver APASL Oncology 2021.

Never in the history of humankind should we now be more united in our efforts to confront a common deadly enemy - COVID-19. To win this war for the human race, we need knowledge from all fronts, to be united in our critical thinking and experiences. So far, tremendous effort has been exercised to control new human transmission.

To this end, we APASL have organized frequent APASL Hepatology Webinars since last year and are webcasting those high-quality educational webinars through our official “APASL Cast” with a large number of registrants.

On the other side, as the new series of the APASL official meeting; Annual meeting and Single topic conferences with a variety of topics, the “APASL Oncology” meeting has been launched from this year, and this event marks the memorable 1st conference of “APASL Oncology” in Tokyo (hybrid-style meeting) focusing particularly on the study of “Hepatic Oncology”. We anticipate active discussion with experts in various field to enlighten us on the most recent Asia-Pacific data in epidemiology, diagnostics, treatment, and all of “Oncology”.

We look forward to your participation!

Yours sincerely,

Masao Omata M.D.
Honorary President, APASL Oncology 2021 Tokyo
Steering Committee of APASL
Professor Emeritus, The University of Tokyo
President, Yamanashi Central and Kita Hospitals
Welcome Message

Dear Colleagues,

On behalf of the Organizing Committee, we would like to welcome you to the Asian Pacific Association for the Study of the Liver APASL Oncology 2021, which will be held on December 17-18 2021 in Tokyo, Japan as a hybrid-style meeting.

This conference had originally been scheduled for December 2020; however, it was rescheduled because of the COVID-19 pandemic. We deeply appreciate your understanding and cooperation. The scientific program will consist of invited lectures, plenary sessions, symposia, and free papers on significant developments on the theme of “Your Gateway to Oncology in the Asia-Pacific Region”. The program will also provide the latest information and fresh ideas for hepatologists and oncologists in this area.

We have accepted all categories of Hepatology and Oncology abstracts, including case reports. We appreciate your submission of abstracts and anticipate a large number of attendants, which will stimulate active discussions.

APASL Oncology 2021 will combine the physical event at The Prince Park Tower Tokyo, Japan in the Centre of Tokyo, with a Virtual Meeting platform for a unique experience bringing both the in-person and virtual community together. Webcast video presentations will be connected with physical presentations and sessions including virtual interactions, live commentary, online chat and discussion.

A delegation of experts from all over the world is expected to attend this conference. We are sure that this will provide an excellent opportunity for those of us in the Asian Pacific region to share the latest views, values, experience, and practice, and greatly contribute to this field. We are looking forward to seeing you soon in Tokyo or through the online webinar.

With warmest regards,

Mitsuhiko Moriyama, M.D.
President, APASL Oncology 2021 Tokyo
Professor and Chairman, Division of Gastroenterology and Hepatology
Department of Internal Medicine, Nihon University School of Medicine
### Invited Guest Speakers/Chairs/Scientific Committee

#### Invited Guest Speakers/Chairs/Scientific Committee from Overseas

<table>
<thead>
<tr>
<th>Name</th>
<th>Country/Region</th>
<th>Name</th>
<th>Country/Region</th>
<th>Name</th>
<th>Country/Region</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr. Oidov BaatarKhuu</td>
<td>Mongolia</td>
<td>Dr. Seth J. Karp</td>
<td>USA</td>
<td>Dr. Gamal Shiha</td>
<td>Egypt</td>
</tr>
<tr>
<td>Dr. Pei Jer Chen</td>
<td>Taiwan</td>
<td>Dr. Do Young Kim</td>
<td>Korea</td>
<td>Dr. Simone Strasser</td>
<td>Australia</td>
</tr>
<tr>
<td>Dr. Ann-Li Cheng</td>
<td>Taiwan</td>
<td>Dr. George Lau</td>
<td>China</td>
<td>Dr. Pil Soo Sung</td>
<td>Korea</td>
</tr>
<tr>
<td>Dr. Wan Long Chung</td>
<td>Taiwan</td>
<td>Dr. Cosmas R.A. Lesmana</td>
<td>Indonesia</td>
<td>Dr. Tung-Hung Su</td>
<td>Taiwan</td>
</tr>
<tr>
<td>Dr. Massimo Colombo</td>
<td>Italy</td>
<td>Dr. Chun-Jen Liu</td>
<td>Taiwan</td>
<td>Dr. Taraweesak Tanwandee</td>
<td>Thailand</td>
</tr>
<tr>
<td>Dr. Levent Doğanay</td>
<td>Turkey</td>
<td>Dr. Mumin-At-Mahim</td>
<td>Bangladesh</td>
<td>Dr. Arndt Vogel</td>
<td>Germany</td>
</tr>
<tr>
<td>Dr. A. Kadir Dokmeci</td>
<td>Turkey</td>
<td>Dr. Rakhi Maiwall</td>
<td>India</td>
<td>Dr. Lai Wei</td>
<td>China</td>
</tr>
<tr>
<td>Dr. Rino Gani</td>
<td>Indonesia</td>
<td>Dr. Necati Örmece</td>
<td>Turkey</td>
<td>Dr. Jin Mo Yang</td>
<td>Korea</td>
</tr>
<tr>
<td>Dr. Hasmik Ghazinyan</td>
<td>Armenia</td>
<td>Dr. Young Nyun Park</td>
<td>Korea</td>
<td>Dr. Thomas Yau</td>
<td>China</td>
</tr>
<tr>
<td>Dr. Saeed Hamid</td>
<td>Pakistan</td>
<td>Dr. Dina A. Payawal</td>
<td>Philippines</td>
<td>Dr. Wei-Peng Yong</td>
<td>Singapore</td>
</tr>
<tr>
<td>Dr. Jee-Fu Huang</td>
<td>Taiwan</td>
<td>Dr. Teeruha Piratvisuth</td>
<td>Thailand</td>
<td>Dr. Changhoon Yoo</td>
<td>Korea</td>
</tr>
<tr>
<td>Dr. Chiu Hsu</td>
<td>Taiwan</td>
<td>Dr. Ranjit Ray</td>
<td>USA</td>
<td>Dr. Hong You</td>
<td>China</td>
</tr>
<tr>
<td>Dr. Washim Jafri</td>
<td>Pakistan</td>
<td>Dr. Ratna B. Ray</td>
<td>USA</td>
<td>Dr. Min-Lung Yu</td>
<td>Taiwan</td>
</tr>
<tr>
<td>Dr. Ji Dong Jia</td>
<td>China</td>
<td>Dr. Shiv Kumar Sarin</td>
<td>India</td>
<td>Dr. Man-Fung Yuen</td>
<td>China</td>
</tr>
<tr>
<td>Dr. Jia-Horng Kao</td>
<td>Taiwan</td>
<td>Dr. Manoj K. Sharma</td>
<td>India</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*In alphabetical order*

#### Invited Guest Speakers/Chairs/Scientific Committee from Japan

<table>
<thead>
<tr>
<th>Name</th>
<th>Name</th>
<th>Name</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dr. Hirohiko Aburatsani</td>
<td>Dr. Shuichi Kaneko</td>
<td>Dr. Mitsuhiro Moriyama</td>
<td></td>
</tr>
<tr>
<td>Dr. Shinichiro Aishima</td>
<td>Dr. Tatsuya Kanto</td>
<td>Dr. Kazunari Murakami</td>
<td></td>
</tr>
<tr>
<td>Dr. Norio Akuta</td>
<td>Dr. Hiroaki Kanzaki</td>
<td>Dr. Takamichi Murakami</td>
<td></td>
</tr>
<tr>
<td>Dr. Jun Arai</td>
<td>Dr. Muroe Kasahara</td>
<td>Dr. Akihito Nagahara</td>
<td></td>
</tr>
<tr>
<td>Dr. Yoshinari Asaoka</td>
<td>Dr. Naoya Kato</td>
<td>Dr. Hidenari Nagai</td>
<td></td>
</tr>
<tr>
<td>Dr. Kauki Chayama</td>
<td>Dr. Norifumi Kawada</td>
<td>Dr. Yuko Nagao</td>
<td></td>
</tr>
<tr>
<td>Dr. Tetsuhiro Chiba</td>
<td>Dr. Takumi Kawaguchi</td>
<td>Dr. Sumiko Nagoshi</td>
<td></td>
</tr>
<tr>
<td>Dr. Hironi Enomoto</td>
<td>Dr. Yusuke Kawanuma</td>
<td>Dr. Hidewaki Nakagawa</td>
<td></td>
</tr>
<tr>
<td>Dr. Kenichi Harada</td>
<td>Dr. Kazufumi Kobayashi</td>
<td>Dr. Nobuhiro Nakamoto</td>
<td></td>
</tr>
<tr>
<td>Dr. Kiyoshi Hasegawa</td>
<td>Dr. Takahiro Kodama</td>
<td>Dr. Naoshi Nishida</td>
<td></td>
</tr>
<tr>
<td>Dr. Etsuro Hatano</td>
<td>Dr. Atsumasa Komori</td>
<td>Dr. Shuhei Nishiguchi</td>
<td></td>
</tr>
<tr>
<td>Dr. Yoichi Hiwa</td>
<td>Dr. Mina Komuta</td>
<td>Dr. Takuto Nosaka</td>
<td></td>
</tr>
<tr>
<td>Dr. Hayato Hikita</td>
<td>Dr. Yasuteru Kondo</td>
<td>Dr. Kazuhiro Nono</td>
<td></td>
</tr>
<tr>
<td>Dr. Atsunori Hiraoka</td>
<td>Dr. Keisuke Koroki</td>
<td>Dr. Shuntaro Obi</td>
<td></td>
</tr>
<tr>
<td>Dr. Yosuke Hirotsu</td>
<td>Dr. Masatoshi Kudo</td>
<td>Dr. Sadahisa Ogasawara</td>
<td></td>
</tr>
<tr>
<td>Dr. Masao Honda</td>
<td>Dr. Masayuki Kurosaki</td>
<td>Dr. Masahiro Ogawa</td>
<td></td>
</tr>
<tr>
<td>Dr. Hiroko Ijima</td>
<td>Dr. Shinya Maekawa</td>
<td>Dr. Takamasa Ohki</td>
<td></td>
</tr>
<tr>
<td>Dr. Hiroo Imazu</td>
<td>Dr. Hitoshi Maruyama</td>
<td>Dr. Masayuki Ohtsuka</td>
<td></td>
</tr>
<tr>
<td>Dr. Yuji Iimuro</td>
<td>Dr. Tsutomu Masaki</td>
<td>Dr. Yukiyasu Okamura</td>
<td></td>
</tr>
<tr>
<td>Dr. Masafumi Ikeda</td>
<td>Dr. Ryota Masuzaki</td>
<td>Dr. Hironao Okubo</td>
<td></td>
</tr>
<tr>
<td>Dr. Sadakatsu Ikeda</td>
<td>Dr. Naoki Matsumoto</td>
<td>Dr. Masao Omata</td>
<td></td>
</tr>
<tr>
<td>Dr. Fumio Imazeki</td>
<td>Dr. Yutaka Midorikawa</td>
<td>Dr. Motomyuki Otsuka</td>
<td></td>
</tr>
<tr>
<td>Dr. Hiroo Imazu</td>
<td>Dr. Toshio Miki</td>
<td>Dr. Issei Saeki</td>
<td></td>
</tr>
<tr>
<td>Dr. Hidiki Iwamoto</td>
<td>Dr. Masashi Mizokami</td>
<td>Dr. Michiie Sakamoto</td>
<td></td>
</tr>
<tr>
<td>Dr. Namiki Izumi</td>
<td>Dr. Eishiro Mizukoshi</td>
<td>Dr. Naoya Sakamoto</td>
<td></td>
</tr>
<tr>
<td>Dr. Kenya Kamimura</td>
<td>Dr. Satoshi Mochida</td>
<td>Dr. Reina Sasaki</td>
<td></td>
</tr>
<tr>
<td>Dr. Tatsuo Kanda</td>
<td>Dr. Naoki Morimoto</td>
<td>Dr. Shinpei Sato</td>
<td></td>
</tr>
</tbody>
</table>
Dr. Shuichiro Shiina
Dr. Masahito Shimizu
Dr. Masaya Sugiyama
Dr. Fumitaka Suzuki
Dr. Shinichi Takahashi
Dr. Tadatoshi Takayama
Dr. Haruhiko Takeda
Dr. Tetsuo Takehara
Dr. Junko Tanaka
Dr. Shinji Tanaka
Dr. Yasuhito Tanaka
Dr. Makiko Taniai
Dr. Ryosuke Tateishi
Dr. Katsutoshi Tokushige
Dr. Takuji Torimura
Dr. Hidenori Toyoda
Dr. Kaoru Tuchiya
Dr. Yoshiyuki Ueno
Dr. Kazuomi Ueshima
Dr. Takeji Umemura
Dr. Yoshiyuki Wada
Dr. Takuya Yamagishi
Dr. Taro Yamashita
Dr. Tatsuya Yamashita
Dr. Shintaro Yamazaki
Dr. Yutaka Yasui
Dr. Hiroshi Yatsuhashi
Dr. Osamu Yokosuka
Dr. Hideo Yoshida
Dr. Hitoshi Yoshiji
Dr. Sachiyu Yoshio
Dr. Hiroshi Yotsuyanagi

Organizing Committee

In alphabetical order

Local Organizing Committee

Honorary President: Dr. Masao Omata
President: Dr. Mitsuhiko Moriyama
Vice-President: Dr. Tadatoshi Takayama
Secretary General: Dr. Tatsuo Kanda
Treasurer: Dr. Fumio Imazeki
Vice-Treasurer: Dr. Shunichi Matsuoka
Vice-Treasurer: Dr. Masahiro Ogawa
Vice-Secretary General: Dr. Ryota Masuzaki

APASL Steering Committee

Chairman of Steering Committee: Dr. Shiv Kumar Sarin (India)
President: Dr. Jin Mo Yang (Korea)
Immediate Past President: Dr. Tawesak Tanwandee (Thailand)
President Elect: Dr. Han-Chieh Lin (Taiwan)
Secretary General-cum-Treasurer: Dr. Manoj K Sharma (India)

Past Presidents:

Dr. Laurentius A. Lesmana (Indonesia)
Dr. Jose Sollano (Philippines)
Dr. Masao Omata (Japan)
Dr. Dong Jin Suh (Korea)
Dr. George Lau (China)
Dr. Ji Dong Jia (China)
Dr. Teerha Piratvisuth (Thailand)
Dr. Jia-Horng Kao (Taiwan)
Dr. Darrell Crawford (Australia)
Dr. A. Kadir Dokmeci (Turkey)
Dr. Osamu Yokosuka (Japan)
Dr. Jinlin Hou (China)
Dr. Barjesh Chander Sharma (India)
Dr. Diana A. Payawal (Philippines)
Dr. Rino Gani (Indonesia)

APASL Executive Council

Assistant Secretary: Dr. Hong You (China)

Executive Councils:

Dr. Gulnara Aghayeva (Azerbaijan)
Dr. Chun-Jen Liu (Taiwan)
Dr. Mamun-Al-Mahtab (Bangladesh)
Dr. Rakhi Maiwall (India)
Dr. Simone Strasser (Australia)
Dr. Yaman Tokat (Turkey)
Dr. Yoshiyuki Ueno (Japan)
Conference Information

Registration Fee and Category

<table>
<thead>
<tr>
<th></th>
<th>Pre-Registration until Dec. 10, 2021</th>
<th>On Site</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>APASL Member</strong></td>
<td>JPY 25,000</td>
<td>JPY 30,000</td>
</tr>
<tr>
<td><strong>Non-Member</strong></td>
<td>JPY 35,000</td>
<td>JPY 40,000</td>
</tr>
<tr>
<td><strong>Trainee / Resident</strong></td>
<td>JPY 20,000</td>
<td>JPY 20,000</td>
</tr>
<tr>
<td><strong>Accepted Abstract</strong></td>
<td>JPY 10,000</td>
<td>JPY 10,000</td>
</tr>
<tr>
<td><strong>Submitter</strong></td>
<td>Online: JPY 15,000</td>
<td>Online: JPY 15,000</td>
</tr>
<tr>
<td><strong>Accompanying Person</strong></td>
<td>JPY 5,000</td>
<td>JPY 5,000</td>
</tr>
</tbody>
</table>

JPY=Japanese Yen

*APASL Members who have paid 2021 Membership Fee can apply for discounted registration fee.

*Registration for viewing of On-demand Presentation is available until January 20th 2022.

Online Participation (Style: Zoom Webinar)

- The conference program will be presented as a hybrid style meeting.
- Attendants are able to enter the webinar through Zoom [https://zoom.us/join](https://zoom.us/join) with the ID and Password which they have been informed by the conference secretariat. * For Speakers/Chairs, the secretariat sends an individual invitation link to enter the webinar.
- The lectures will be delivered live or by recorded video. After the presentation, the discussion (Q&A) time will be held according to the moderator’s instructions. Online viewers are able to send textual questions to the Q&A column, and the onsite participants may ask questions using the microphone in the conference room. We anticipate your active discussions.
- After the conference term, the recorded lectures and discussion will be distributed on-demand from the presentation page of APASL Oncology 2021 Website [http://www.apasl-oncology2021.org/](http://www.apasl-oncology2021.org/). The viewing period of the on-demand presentation is scheduled to be from December 20, 2021 through January 20, 2022. The secretariat will receive the questions by e-mail during the on-demand delivery period and will forward them to each speaker.

[Precautions]

- The organizer cannot handle problems such as computer operation, internet connection, video and audio connection. Please solve such problems by yourself. We recommend the following environment.
  
  - We would appreciate it if you could use a PC with as much memory as possible (CPU i5 or more, memory 8 Giga or more).
  - Please connect to the Internet via a wired LAN line as much as possible.
- To transfer or share the ID and password, recording of screens and images is strictly prohibited.
- The internet fee at this online conference will be borne by each attendant.

We cordially solicit your understanding and cooperation.

Onsite Registration/PC Pre-view Hours

<table>
<thead>
<tr>
<th></th>
<th>December 17 (Friday)</th>
<th>December 18 (Saturday)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>7:30-19:30 (JST)</td>
<td>7:30-16:00 (JST)</td>
</tr>
</tbody>
</table>
Onsite-Venue

The Prince Park Tower Tokyo

Address: 4-8-1 Shibakoen Minato, Tokyo 105-8563 Japan
Tel: +81-(0)3-5400-1111
URL: http://www.princehotels.com/parktower/

Location: [From Haneda Airport]
By Train: About 35 minutes to Daimon Station of Toei Subway Asakusa Line (via Keikyu Airport Line and Keikyu Line, Toei Subway Asakusa Line)
By Monorail: About 20 minutes by Tokyo Monorail to Hamamatsucho Station
By Car: About 15 minutes by taxi during normal hours (taking toll road, via Shibakoen Ramp)
[From Nearest Stations]
From Akabanebashi Station of Toei Subway Oedo Line: about 2 minutes on foot
From Shibakoen Station of Toei Subway Mita Line: about 3 minutes on foot
From Daimon Station of Toei Subway Asakusa Line/ Toei Subway Oedo Line: about 9 minutes on foot
From Hamamatsucho Station of JR Line/Tokyo Monorail: about 12 minutes on foot
From Kamiyacho Station of Tokyo Metro Subway Hibiya Line: about 12 minutes on foot

Floor Plan: B2F, The Prince Park Tower Tokyo

Oral Program will be held at following 3 rooms:
Room 1 (Convention Hall A+B)
Room 2 (Convention Hall C)
Room 3 (Convention Hall D)

Registration: Room 4 (Convention Hall E)
Poster Session: Room 4 (Convention Hall E)
Secretariat Room: Room Ichou
Speakers/Chairs Ready Room:
Room Ayame, Kikyou, and Suisen
Cloak: Foyer in front of Convention Hall G
PC Preview Desk: in each Room 1, 2, 3 forward
Instruction for Oral Presentation

The conference program will be presented as a hybrid style meeting.

- An invitation email containing information about the login will be sent to the presenters/moderators through the Zoom system. The login URL will be included in the invitation email.
- We would appreciate it if you could conduct a test connection ahead of the conference.
- The general sessions’ presentation time is 15 minutes. The Oral Free Paper is 7 minutes (5 minutes presentation, 2 minutes discussion).
- After presentation, the discussion time (a question-and-answer session) will be held according to the moderator’s instructions.

[For those who will participate at the onsite venue]
- Please complete your registration of presentation data at the Data Pre-View Desk until 1 hour before your presentation time.
- Please be seated at the “next speaker’s seat” at least 10 minutes before your presentation. The seat will be located forward near the podium.
- The slides which you have submitted in advance for the presentation are prepared on the computer of the podium. Please operate the slides by yourself. Please note that the presenter tool is not available.

[For those who will attend online]
- Please join Zoom at least 20 minutes before your session begins.
- Please turn on the microphone and the camera only when you are speaking.
- The moderator will introduce the presenter at the beginning of each presentation.
- Then, the secretariat will start the presentation video. (In principle, you do not have to share your presentation by yourself.)
- After finishing the presentation, online viewers will send textual questions to the Q & A column, so please follow the moderator’s instructions and answer those questions.
- The following environment is recommended.
  - Create the image resolution in XGA (1024 x 768).
  - Microsoft PowerPoint (2010-2016) can be used as the application software.
  - The fonts that come standard with Microsoft PowerPoint, Times, Arial are recommended.

[Precautions]
- Do not post, modify, distribute or reproduce copyrighted material, trademarks, portrait rights or other property rights in any way without the prior written consent of the owners of these property rights.
- Regarding citations, please specify the source of the citation.
- Please exert caution regarding the protection of personal information such as name, age, surgery date, etc. This could lead to the identification of an individual.
Instruction for Chairs

The conference program will be presented as a hybrid style meeting.

- An invitation email that contains information about the login will be sent to the presenters/moderators through the Zoom system. The login URL will be included in the invitation email.
- At the real time webinar, the recorded lecture will be presented, and speakers/chairs are requested to join the discussion time. The presentation and Q & A session will be delivered live.
- The general oral presentation time is 15 minutes. The Oral Free Paper is 7 minutes (5 minutes presentation, 2 minutes discussion).
- After presentation, the discussion time (a question-and-answer session) will be held according to the moderator’s instructions. The online viewer will send questions in the Q & A column. The onsite participants will ask questions using the microphone at the conference hall.
- After the conference, the recorded video will be posted on the on-demand presentation page.

[For Chairs who will participate at the onsite conference venue]
Please be seated at the “next chair’s seat” at least 10 minutes before the session will start. The seat will be located forward near the stage.

[For Chairs who will attend online]

- Please join Zoom at least 20 minutes before your session begins.
- Please turn on the microphone and the camera only when you are speaking. Please mute the microphone otherwise.
- Please introduce the presenter at the beginning of each presentation. Then, the secretariat will start the presentation video, or the speaker will start his/her presentation on-site.
- After finishing the presentation, please turn on the microphone and camera again. Online viewers will send textual questions to the Q&A column, and the onsite participants will ask questions using the microphone in the conference room. So please convey those questions and moderate the discussion.
- The following environment is recommended.
  - Create the image resolution in XGA (1024 x 768).
  - Microsoft PowerPoint (2010-2016) can be used as the application software.
  - The fonts that come standard with Microsoft PowerPoint, Times, Arial are recommended.
Instruction for On-Site Poster Presentation

[About presentation style]

• A panel width 90cm×length 210cm will be provided for each poster as following sample.
• Poster number will be prepared by secretariat.
• Title and author’s name are required to be prepared by each presenter.
• Pins for display will be provided at each poster panel.
• Location: Poster Session will be located in (or foyer of) the Room 4, B2 Floor, The Prince Park Tower Tokyo.
• Schedule: On-site Poster Presentation is scheduled as follows.
  Poster Attachment: 7:30-11:00 on December 17 (Friday)
  Poster Presentation: 13:40-14:20 on December 18 (Saturday)
  Poster Removal: 16:00-17:30 on December 18 (Saturday)
• Presentation Time: 5 minutes (3 minutes presentation; 2 minutes discussion) for each presentation.
• For those who have not removed posters until above removal time, please accept that the secretariat will discard any posters that have remained.
• Awarding Ceremony: The Awardees will be presented at the Closing Ceremony during 17:40-17:50 on December 18 (Saturday).

Poster Panel

Poster Panel
Instruction for E-Poster Presentation

[About presentation style]
The conference program will be presented as a hybrid style meeting.
The poster presenters who are not able to attend physically to the conference venue, are requested
to present as the E-Poster.

- The E-Poster session will be available through APASL Oncology 2021 Website from the
conference term at http://www.apasl-oncology2021.org
- After the conference, the presentation will be posted on the on-demand presentation page.
- Please send your presentation (PowerPoint File 4:3) in advance to the secretariat as follows.
- Microsoft PowerPoint (2010-2016) can be used as the application software.
- File size is limited to 20 MB.
- The number of PPT slides is limited to 15 slides including the title and COI slides.
- Requested PowerPoint size is 4: 3.
- Awarding Ceremony: The Awardees will be presented at the Closing Ceremony during 17:40-17:50 on
  December 18 (Saturday).

[Precautions]
- Do not post, modify, distribute, or reproduce copyrighted material, trademarks, portrait rights,
or other property rights in any way without the prior written consent of the owners of these
  property rights.
- Regarding citations, please specify the source of the citation.
- Please exert caution regarding the protection of personal information such as name, age,
surgery date, etc. This could lead to the identification of an individual.
- Please pay particular attention to images that may be considered problematic when viewed by
  the public at this conference.

If you have any questions, please contact the secretariat below.
Contact: APASL Oncology 2021 Tokyo Congress Secretariat
c/o Academia Support Japan
Email: info@apasl-oncology2021.org
Tel: +81-3-6380-0102 Fax: +81-3-6380-0103
URL http://www.apasl-oncology2021.org
Awards

Excellent papers will be awarded as “Presidential Award” or “Young Investigator Award”.
Awarding Ceremony: The Awardees of Free Papers will be presented at the Closing Ceremony during 17:40-17:50 (Japan Standard Time) on December 18 (Saturday).

Presidential Award

“APASL Oncology 2021 Presidential Award” will be awarded to whom performed the most excellent presentation in APASL Oncology 2021 to encourage to further their research and progress.

Young Investigator Award (Under 40 years old)

The purpose of the “APASL Oncology 2021 Young Investigator Award” is to praise outstanding examples of excellence amongst those involved in research training in the early stages of their career.

Contact

APASL Oncology 2021 Scientific Secretariat
Division of Gastroenterology and Hepatology
Department of Internal Medicine, Nihon University School of Medicine

APASL Oncology 2021 Congress Secretariat
c/o Academia Support Japan
Email: info@apasl-oncology2021.org
Tel: +81-3-6380-0102 Fax: +81-3-6380-0103

APASL Central Office (APASL Secretariat-Tokyo)
Asian Pacific Association for the Study of the Liver [APASL]
1-24-7-920, Shinjuku, Shinjuku-ku, Tokyo, 160-0022 Japan
Email: apasl_secretariat@apasl.info
Tel: +81-3-5312-7686 Fax: +81-3-5312-7687
Sponsors and Support Organization

The Organizing Committee of the APASL Oncology 2021 Tokyo would like to express sincere gratitude to the following sponsors and organizations for supporting this conference.

**Diamond Sponsor**

Chugai Pharmaceutical Co., Ltd.

**Platinum Sponsor**

AbbVie GK

**Gold Sponsors**

Eisai Co., Ltd.  
Incyte Biosciences Japan GK  
Miyarisan Pharmaceutical Co., Ltd.

MSD K.K.  
Sysmex Corporation
Silver Sponsors

AstraZeneca  
Gilead Sciences K.K.  
Mitsubishi Tanabe Pharma Corporation  
Mitsuwadai General Hospital

Otsuka Pharmaceutical Co., Ltd.  
Takeda Pharmaceutical Co., Ltd.  
Towa Pharmaceutical Co., Ltd.  
In alphabetical order

Bronze Sponsors

Akiru Municipal Medical Center  
Ando Hospital Medical Corporation  
Asahi Kasei Pharma Corporation  
ASKA Pharmaceutical Co., Ltd.  
Astellas Pharma Inc.  
Bayer Yakuhin, Ltd.  
Canon Medical Systems  
Chikuma Central Hospital  
Cytori Therapeutics Inc.  
Daiichi Sankyo Co., Ltd.  
Dainippon Sumitomo Pharma Co., Ltd.  
Eli Lilly Japan K.K.  
Honda R&D Co., Ltd.  
Inogashira Corporation  
Janssen Pharmaceutical K.K.  
Medikit Co., Ltd.

Mikuni Naika-Ganka Clinic  
Mochida Pharmaceutical Co., Ltd.  
Mylan EPD G.K.  
NexusAgent.inc  
Niiza Shiki Central General Hospital  
Nippon Boehringer Ingelheim Co., Ltd.  
Nobelpharma Co., Ltd.  
Nonakatokokai Seifuso Hospital  
Philips Japan, Ltd.  
Shino-Test Corporation  
Stryker Japan K.K.  
Syoutokukai Sekishindo Hospital  
Terumo Corporation  
TKP Medicalink Corporation  
Tokyo Health Service Association  
ZERIA Pharmaceutical Co., Ltd.

Support Organizations

Alumni Association, Nihon University School of Medicine

The Japan Society of Hepatology

Tokyo Convention & Visitors Bureau

The Uehara Memorial Foundation

In alphabetical order
## Program at a Glance

### Day 1: December 17 (Friday) 2021

<table>
<thead>
<tr>
<th>Time (JST)</th>
<th>Room 1 (A+B)</th>
<th>Room 2 (C)</th>
<th>Room 3 (D)</th>
<th>Room 4 (E)</th>
<th>Web</th>
</tr>
</thead>
<tbody>
<tr>
<td>7:50</td>
<td>Opening Ceremony</td>
<td>8:00-9:00 Morning Seminar (1) (Chugai Pharmaceutical Co., Ltd.)</td>
<td>8:00-9:00 Morning Seminar (2) (Otsuka Pharmaceutical Co., Ltd.)</td>
<td></td>
<td>Poster Set up</td>
</tr>
<tr>
<td>8:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:00</td>
<td>9:10-10:40 Session 1 Molecular Mechanism of HCC (1)</td>
<td>9:05-10:50 Session 6 Surgery and Transplantation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td>10:50-12:20 Session 2 Intermediate-stage HCC (1)</td>
<td>11:00-12:30 Session 7 HCC in Asia, Epidemiology (1)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td>13:40-14:20 President Lecture (Towa Pharmaceutical Co., Ltd.)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td>14:30-16:00 Session 3 Intermediate-stage HCC (2)</td>
<td>14:30-16:00 Session 8 HCC in Asia, Epidemiology (2)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td></td>
<td></td>
<td>14:30-15:30 Educational Seminar (1) (Miyarisan Pharmaceutical Co., Ltd.)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td>16:10-17:40 Session 4 Pathology of HCC</td>
<td>16:10-17:40 Session 9 Management of HCC and Complications during TKI Treatment</td>
<td>15:40-16:50 Oral Free Papers (2)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>18:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>19:00</td>
<td>17:50-19:20 Session 5 Oncoimmunotherapy for HCC</td>
<td>17:50-19:20 Session 10 HCC after SVR</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>20:00</td>
<td>19:30-20:30 Evening Seminar (Incyte Biosciences Japan GK)</td>
<td></td>
<td>20:00-22:30 APASL Hepatology Webinar “Editor’s Choice” collaborated with AASLD</td>
<td></td>
<td></td>
</tr>
<tr>
<td>22:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Notes:
- **Opening Ceremony**: 8:00-9:00
- **Morning Seminar**: 8:00-9:00
- **Poster Set up**: 9:10-10:06
- **Luncheon Seminar**: 12:30-13:30
- **Luncheon Seminar**: 12:40-13:40
- **Poster Viewing**: 14:30-15:30
- **E-Poster Presentation**: 15:40-16:50

**Session Time**
- Opening Ceremony: 8:00-9:00
- Morning Seminar: 8:00-9:00
- Poster Set up: 9:10-10:06
- Luncheon Seminar: 12:30-13:30
- Luncheon Seminar: 12:40-13:40
- Poster Viewing: 14:30-15:30
- Educational Seminar: 14:30-15:30
- E-Poster Presentation: 15:40-16:50

**Session Topics**
- **Molecular Mechanism of HCC (1)**
- **Surgery and Transplantation**
- **HCC in Asia, Epidemiology (1)**
- **Intermediate-stage HCC (1)**
- **Intermediate-stage HCC (2)**
- **HCC in Asia, Epidemiology (2)**
- **Pathology of HCC**
- **Management of HCC and Complications during TKI Treatment**
- **Oncoimmunotherapy for HCC**
- **HCC after SVR**

**Webinar Information**
- **APASL Hepatology Webinar “Editor’s Choice”**
- **collaborated with AASLD**
## Program at a Glance

### Day 2: December 18 (Saturday) 2021

<table>
<thead>
<tr>
<th>Time (JST)</th>
<th>Room 1 (A+B)</th>
<th>Room 2 (C)</th>
<th>Room 3 (D)</th>
<th>Room 4 (E)</th>
<th>Web</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00</td>
<td>8:00-9:00 Morning Seminar (3) (Mitsubishi Tanabe Pharma Corporation)</td>
<td>8:00-9:00 Morning Seminar (4) (Takeda Pharmaceutical Co., Ltd.)</td>
<td>8:00-9:00 Morning Seminar (5) (AstraZeneca)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:00</td>
<td>9:10-10:40 Session 11 Molecular Mechanism of HCC (2)</td>
<td>9:10-10:40 Session 15 COVID-19 in Japan</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00</td>
<td>10:50-12:20 Session 12 HAIC, TACE, RFA, Radiation</td>
<td>10:50-12:20 Session 16 Diagnosis of HCC</td>
<td>11:00-12:00 Educational Seminar (2) (AbbVie GK)</td>
<td></td>
<td>Poster Viewing</td>
</tr>
<tr>
<td>11:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>E-Poster Presentation</td>
</tr>
<tr>
<td>12:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>14:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:00</td>
<td>14:30-16:00 Session 13 Intermediate-stage HCC (3)</td>
<td>14:30-16:00 Session 17 Intermediate-stage HCC (4)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td>16:10-17:40 Session 14 Intermediate-stage HCC (5)</td>
<td>16:10-17:40 Session 18 Intermediate-stage HCC (6)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>17:40-17:50</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Awarding Ceremony</td>
</tr>
<tr>
<td>17:50-18:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Closing Ceremony</td>
</tr>
<tr>
<td>18:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Note:** The program includes seminars, discussions, and luncheons, with specific sessions dedicated to various topics such as HCC (Hepatocellular Carcinoma), COVID-19, and other medical topics. The sessions are held in different rooms, with some activities being available online (E-Poster Presentation).
Scientific Program

Day 1: December 17 (Friday) 2021
Room 1

7:50-8:00 Opening Ceremony

Dr. Mitsuhiko Moriyama (President of APASL Oncology 2021)

8:00-9:00 Morning Seminar (1) (Sponsored by Chugai Pharmaceutical Co., Ltd.)
Chair: Dr. Masao Omata (Japan)

Toward Further Advancement of Molecular Targeted Therapy Using Liquid Biopsy in HCC
Dr. Sadakatsu Ikeda (Japan)

9:10-10:40 Session 1: Molecular Mechanism of HCC (1)
Chairs: Dr. Ranjit Ray (USA)/Dr. Naoshi Nishida (Japan)

9:10-9:25 1-1 Risk Assessment of Hepatocellular Carcinoma Development-clinical and Molecular Perspective
Dr. Ryota Masuzaki (Japan)

9:25-9:40 1-2 Role of FGF19/FGFR4 Signaling and Potential of Serum FGF19 as a Biomarker in Hepatocellular Carcinoma
Dr. Tetsuhiro Chiba (Japan)

9:40-9:55 1-3 Accumulation of Molecular Aberrations Distinctive to Hepatocellular Carcinoma Progression
Dr. Yutaka Midorikawa (Japan)

9:55-10:10 1-4 Linking IncRNA Linc-Pint with Liver Disease
Dr. Ratna B. Ray (USA)

10:10-10:25 1-5 Genetic and Epigenetic Basis of Pediatric Liver Tumors
Dr. Hiroyuki Aburatani (Japan)

10:25-10:40 Discussion Time

10:50-12:20 Session 2: Intermediate-stage HCC (1) (TKI, Lenvatinib)
Chairs: Dr. Tawesak Tanwandee (Thailand)/Dr. Masafumi Ikeda (Japan)

10:50-11:05 2-1 Analysis for Transition of Molecular Target Agent Therapy and Prognosis in Advanced Hepatocellular Carcinoma
Dr. Kazufumi Kobayashi (Japan)

11:05-11:20 2-2 HCC Following Hepatitis C Virus Eradication
Dr. Massimo Colombo (Italy)

11:20-11:35 2-3 Integrating Systemic Therapy into Multidisciplinary Treatment of HCC
Dr. Ann-Lii Cheng (Taiwan)
11:35-11:50  2-4 Systemic Treatment Including Lenvatinib in Patients with BCLC-B Stage Hepatocellular Carcinoma
   Dr. Atsushi Hiraoka (Japan)

11:50-12:05  2-5 Identification of Tumor Factors of Hepatocellular Carcinoma that Decrease the Efficacy of Immune Checkpoint Inhibitors
   Dr. Masao Honda (Japan)

12:05-12:20  Discussion Time

12:30-13:30 Luncheon Seminar (1)  (Sponsored by Chugai Pharmaceutical Co., Ltd.)
   Chair: Dr. Masatoshi Kudo (Japan)
   Novel Cancer Immunotherapy for Hepatocellular Carcinoma: Evidence and Management
   Dr. Masafumi Ikeda (Japan)
   Exploring Next-Gen Systemic Therapy for HCC: What Have We Learned?
   Dr. Ann-Lii Cheng (Taiwan)

13:40-14:20 President Lecture  (Sponsored by Towa Pharmaceutical Co., Ltd.)
   Chair: Dr. Masao Omata (Japan)
   Considering the Occurrence of Liver Cancer from Chronic Hepatitis C / Cirrhosis in Japan
   Dr. Mitsuhiko Moriyama (President of APASL Oncology 2021)

14:30-16:00 Session 3: Intermediate-stage HCC (2)
   Chairs: Dr. George Lau (China)/Dr. Atsumasa Komori (Japan)/Dr. Tsutomu Masaki (Japan)

14:30-14:45  3-1 Treatment Strategy for Intermediate Stage HCC
   Dr. Masafumi Ikeda (Japan)

14:45-15:00  3-2 Paradigm Shift with Drug Therapy in the Treatment of Intermediate-Stage Hepatocellular Carcinoma
   Dr. Tatsuya Yamashita (Japan)

15:00-15:15  3-3 Treatment Strategy for Intermediate Stage HCC with Consideration of Maintaining Liver Function
   Dr. Naoya Kato (Japan)

15:15-15:30  3-4 Systemic Therapy in the Intermediate Stage HCC: Current Evidence and Future Perspective
   Dr. Changhoon Yoo (Korea)

15:30-15:45  3-5 Treatment Strategy of Intermediate-stage HCC: ABC Conversion Therapy
   Dr. Masatoshi Kudo (Japan)

15:45-16:00  Discussion Time

16:10-17:40 Session 4: Pathology of HCC
   Chairs: Dr. Shinichi Aishima (Japan)/Dr. Kenichi Harada (Japan)/Dr. Michie Sakamoto (Japan)

16:10-16:25  4-1 Tumour Heterogeneity of HCC and Its Clinical Relevance
   Dr. Mina Komuta (Japan)
16:25-16:40  4-2 Pathological Features of Tumor Microenvironment of HCC  
            Dr. Michiie Sakamoto (Japan)

16:40-16:55  4-3 Genomic Structures and Carcinogenesis of HBV Integrations in Liver Cancer  
            Dr. Hidewaki Nakagawa (Japan)

16:55-17:10  4-4 Update in HCC Pathology  
            Dr. Young Nyun Park (Korea)

17:10-17:25  4-5 Morphological Subtypes of Hepatocellular Carcinoma  
            Dr. Shinichi Aishima (Japan)

17:25-17:40  Discussion Time

17:50-19:20 Session 5: Oncoimmunotherapy for HCC

Chairs: Dr. Shiv K. Sarin (India)/Dr. Masao Omata (Japan)

17:50-18:05  5-1 Mechanism of Resistance to Immunotherapy for Hepatocellular Carcinoma  
            Dr. Kazuomi Ueshima (Japan)

18:05-18:20  5-2 Dramatic Transformation of Treatments in Patients with Advanced Hepatocellular Carcinoma  
            Dr. Sadahisa Ogasawara (Japan)

18:20-18:35  5-3 Oncoimmunotherapy for HCC (Tentative)  
            Dr. Thomas Yau (China)

18:35-18:50  5-4 Leukotrienes Derived from Tumor-Infiltrating M2 Macrophages Promote the Progression of Hepatocellular Carcinoma  
            Dr. Takuto Nosaka (Japan)

18:50-19:05  5-5 Multiomics Profiling Identifies the Link between Intra-tumor Steatosis and Immune-exhaustion in Non-viral HCC  
            Dr. Takahiro Kodama (Japan)

19:05-19:20  Discussion Time

19:30-20:30 Evening Seminar (Sponsored by Incyte Biosciences Japan GK)

Chair: Dr. Yukiyasu Okamura (Japan)

New Personalized Approach for Intrahepatic Cholangiocarcinoma Based on Cancer Genomic Diagnosis in Japan  
            Dr. Naoya Kato (Japan)

Pemigatinib in Cholangiocarcinoma: Targeting FGFR2 Fusions  
            Dr. Arndt Vogel (Germany)
Day 1: December 17 (Friday) 2021
Room 2

8:00-9:00  Morning Seminar (2) (Sponsored by Otsuka Pharmaceutical Co., Ltd.)
Chair: Dr. Naoya Kato (Japan)

The Usefulness of Tolvaptan as a Treatment of Hepatic Edema among Advanced HCC Patients
Dr. Takamasa Ohki (Japan)

Clinical Symptoms of Liver Diseases: Pathogenesis and Treatment
Dr. Tatsuo Kanda (Japan)

9:05-10:50 Session 6: Surgery and Transplantation
Chairs: Dr. Seth J. Karp (USA)/Dr. Tadatoshi Takayama (Japan)

9:05-9:20  6-1 Placental Stem Cell Transplantation Prevented Disease Development in
Ornithine Transcarbamylase Deficiency Model Mice
Dr. Toshio Miki (Japan)

9:20-9:35  6-2 Minimal Invasive Hepatectomy in the Post-SVR Era
Dr. Yuji Iimuro (Japan)

9:35-9:50  6-3 Surgery for Perihilar Cholangiocarcinoma: Resection and Transplantation
Dr. Masayuki Ohtsuka (Japan)

9:50-10:05  6-4 Management of Hepatocellular Carcinoma “Current Therapeutic Options”
Dr. Washim Jafri (Pakistan)

10:05-10:20  6-5 Proposal of Resectability for Hepatocellular Carcinoma for Future Clinical Trial
Dr. Etsuro Hatano (Japan)

10:20-10:35  6-6 Hepatoblastoma Management: From Resection To Transplantation
Dr. Mureo Kasahara (Japan)

10:35-10:50 Discussion Time

11:00-12:30  Session 7: HCC in Asia, Epidemiology (1)
Chairs: Dr. Wan Long Chuang (Taiwan)/Dr. Necati Örmeci (Turkey)/Dr. Fumio Imazeki (Japan)

11:00-11:15  7-1 HCC in China, Epidemiology (Tentative)
Dr. Lai Wei (China)

11:15-11:30  7-2 Epidemiological Aspects of HCC Prevention in Asia-Pacific
Dr. Manoj K Sharma (India)

11:30-11:45  7-3 Changing Epidemiology of Hepatocellular Carcinoma in Taiwan
Dr. Wan-Long Chuang (Taiwan)

11:45-12:00  7-4 The Magnified Challenge of HCC in Bangladesh in the Context of COVID-19 Pandemic
Dr. Mamun-Al Mahtab (Bangladesh)

12:00-12:15  7-5 HCC Caused by Hepatitis Delta Virus Infection in Asia-Pacific
Dr. Saeed Hamid (Pakistan)

12:15-12:30 Discussion Time
12:40-13:40 Luncheon Seminar (2) (Sponsored by Sysmex Co., Ltd.)
Chair: Dr. Jia-Horng Kao (Taiwan)

M2BPGi for Liver Fibrosis and Outcome Prediction
Dr. Tung-Hung Su (Taiwan)

14:30-16:00 Session 8: HCC in Asia, Epidemiology (2)
Chair: Dr. Hasmik Ghazinyan (Armenia) / Dr. Tatsuya Kanto (Japan) / Dr. Osamu Yokosuka (Japan)

14:30-14:45 8-1 Epidemiology Hepatocellular Carcinoma (HCC) in Thailand
Dr. Teerha Piratvisuth (Thailand)

14:45-15:00 8-2 Hepatocellular Carcinoma in Indonesia: Immunology View
Dr. Rino Gani (Indonesia)

15:00-15:15 8-3 Global Epidemiology & Risk Factors of Hepatocellular Carcinoma
Dr. Man-Fung Yuen (China)

15:15-15:30 8-4 Epidemiology of HCC in Mongolia
Dr. Oidov Baatarkhuu (Mongolia)

15:30-15:45 8-5 Epidemiology of Viral Hepatitis and HCC in Japan
Dr. Junko Tanaka (Japan)

15:45-16:00 Discussion Time

16:10-17:40 Session 9: Management of HCC and Complications during TKI Treatment
Chair: Dr. A. Kadir Dokmeci (Turkey) / Dr. Diana A. Payawal (Philippines) / Dr. Tetsuo Takehara (Japan)

16:10-16:25 9-1 HCC Treatment in JRCMC (Japanese Red Cross Medical Center)
Dr. Hideo Yoshida (Japan)

16:25-16:40 9-2 Management of Adverse Event from the Pharmacological Perspective in Patients with Hepatocellular Carcinoma Using Tyrosine Kinase Inhibitor
Dr. Hironao Okubo (Japan)

16:40-16:55 9-3 Management of HCC Patient with Portal Vein Thrombosis
Dr. Shiv Kumar Sarin (India)

16:55-17:10 9-4 Contrast-enhanced US-based Assessment of HCC Hemodynamics Related to Systemic Treatment
Dr. Hitoshi Maruyama (Japan)

17:10-17:25 9-5 Effective Prevention of TKI-related Vascular Damage induced Adverse Events and Maintenance of Hepatic Function by Dried Bonito Broth and Histidine
Dr. Kenya Kamimura (Japan)

17:25-17:40 Discussion Time

17:50-19:20 Session 10: HCC after SVR
Chair: Dr. Shuhei Nishiguchi (Japan) / Dr. Yasuhito Tanaka (Japan) / Dr. Hiroshi Yatsuhashi (Japan)

17:50-18:05 10-1 Rapid Hepatitis C Virus Clearance by Antivirals Correlates with Immune Status of Infected Patients and Decreased Immune Related Cytokines and Chemokines
Dr. Reina Sasaki (Japan)
18:05-18:20 10-2 The Clinical and Pathogentic Significance of HCC after Viral Eradication
Dr. Min-Lung Yu (Taiwan)

18:20-18:35 10-3 Risk of Hepatocellular Carcinoma After Sustained Virological Response in Hepatitis C Virus Infection
Dr. Yoichi Hiasa (Japan)

18:35-18:50 10-4 Development of HCC in Treated HBV Patients
Dr. Jia-Horng Kao (Taiwan)

18:50-19:05 10-5 Gene Expression Signature Associated with HCC Development after HCV Eradication
Dr. Yasuhiro Tanaka (Japan)

19:05-19:20 Discussion Time

20:00-22:30 APASL Hepatology Webinar “Editor’s Choice” Collaborated with AASLD
Day 1: December 17 (Friday) 2021
Room 3

9:10-10:06  Oral Free Papers (1)

Chairs: Dr. Jun Arai (Japan)/Dr. Takumi Kawaguchi (Japan)/Dr. Naoya Sakamoto (Japan)

9:10-9:17  #10046 Surgical Treatment for Multinodular HCC with Right Hepatic Vein Tumor Thrombosis: A Case Report
Dr. Giang Nguyen (Viet Nam)

9:17-9:24  #10006 A Case with HCC Successfully Treated with Prednisone for Atezolizumab-Associated Grade 3 Colitis
Dr. Takahiro Fuji (Japan)

9:24-9:31  #10045 New Research Trends in Onco-carcinogenesis and Nutritional Background Linked with Chronic Inflammation, Iron (Fe) Deposition, and Metabolic Changes
Dr. Kenichi Furuya (Japan)

9:31-9:38  #10061 Case reports of HCC with IVC and Rt. Atrium Tumor Thrombus and Extension into Left Renal Vein
Dr. Parimita Barua (India)

9:38-9:45  #10005 Novel Immuno-Oncotherapy against HCC by Targeting MICA
Dr. Yumi Otoyama (Japan)

9:45-9:52  #10066 Synergistic Nanoassemblies with Enhanced Cancer Chemo-Immunotherapy
Dr. Xiaowei Shi (China)

9:52-9:59  #10012 Various Uses of Ramucirumab in Real World Practice for Patients with Hepatocellular Carcinoma
Dr. Naoya Kanogawa (Japan)

9:59-10:06 #10049 Regorafenib and its metabolites could induce NK cell-mediated cytotoxicity in HCC by targeting ADAM9
Dr. Jun Arai (Japan)

12:30-13:30  Luncheon Seminar (3) (Sponsored by Eisai Co., Ltd./MSD K.K.)
Chair: Dr. Shuntaro Obi (Japan)

LEN-TACE Sequential Therapy as a Therapeutic Strategy for Intermediate-stage Hepatocellular Carcinoma
Dr. Yoshiyuki Wada (Japan)

Positioning of Hepatic Arterial Infusion Chemotherapy and Lenvatinib for Advanced Hepatocellular Carcinoma
Dr. Tatsuya Yamashita (Japan)

14:30-15:30  Educational Seminar (1) (Sponsored by Miyarisan Pharmaceutical Co., Ltd.)
Chair: Dr. Tadatoshi Takayama (Japan)

Role of Gut Microbiota in Liver Disease and Carcinogenesis
Dr. Nobuhiro Nakamoto (Japan)
15:40-16:50  Oral Free Papers (2)

**Chairs: Dr. Hidenari Nagai (Japan)/Dr. Yuko Nagaoki (Japan)**

15:40-15:47  #10004  **Particle Radiotherapy for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis**
            Dr. Yoshiro Matsuo (Japan)

15:47-15:54  #10024  **Efficacy and Safety of Lenvatinib for Patients with Advanced Hepatocellular Carcinoma in Japan**
            Dr. Tadashi Namisaki (Japan)

15:54-16:01  #10020  **HCC Surveillance Remains Cost-effective Long after Hepatitis B Surface Antigen Loss: A 12-year Study**
            Dr. Terry Cheuk-Fung Yip (Japan)

16:01-16:08  #10064  **Hepatocellular Carcinoma Emergence in Armenia: Outcome of Multiple Risk Factors, 2019-2020**
            Dr. Hasmik Levon Ghazinyan (Armenia)

16:08-16:15  #10058  **Nucleic Acid Analog Therapy and Liver Carcinogenesis in Patients with Chronic Hepatitis B**
            Dr. Makoto Moriyama (Japan)

16:15-16:22  #10029  **Impact of Viral Eradication by DAA on Clinical Outcome after Treatment for HCV Associated HCC**
            Dr. Yuko Nagaoki (Japan)

16:22-16:29  #10047  **The Comprehensive Prognosis of Chronic Hepatitis C after DAA Therapy for Chronic Hepatitis C**
            Dr. Yuki Kanayama (Japan)

16:29-16:36  #10023  **Comparison of HBV Reactivation in HCC Patients Who Received TKI and TKI with PD-1 Inhibitor**
            Dr. Jin Lei (China)

16:36-16:43  #10067  **Occult Hepatitis B Virus Infection in Patients with HCV-Related Hepatocellular Carcinoma**
            Dr. Muhammad Abdel-Gawad (Egypt)

16:43-16:50  #10069  **Bone Mineral Density in Patients with Non-Alcoholic Fatty Liver Disease**
            Dr. Muhammad Abdel-Gawad (Egypt)
# Day 2: December 18 (Saturday) 2021

## Room 1

### 8:00-9:00 Morning Seminar (3) (Sponsored by Mitsubishi Tanabe Pharma Corporation)
*Chair: Dr. Katsutoshi Tokushige (Japan)*

- **New Findings and Future Prospects, Based on Japanese Patients of Histological Proven NAFLD in Toranomon Hospital**
  - Dr. Norio Akuta (Japan)

### 9:10-10:40 Session 11: Molecular Mechanism of HCC (2)
*Chairs: Dr. Lai Wei (China)/Dr. Shuichi Kaneko (Japan)/Dr. Shinji Tanaka (Japan)*

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>9:10</td>
<td>Dr. Hayato Hikita (Japan)</td>
<td>11-1 The Interaction of Hepatoma Cells and Stromal Cells Via IL-6 Family Cytokines</td>
</tr>
<tr>
<td>9:25</td>
<td>Dr. Motoyuki Otsuka (Japan)</td>
<td>11-2 Impairment of Homologous Recombination by HBx as the Mechanism for HBV-Related Hepatocarcinogenesis</td>
</tr>
<tr>
<td>9:40</td>
<td>Dr. Taro Yamashita (Japan)</td>
<td>11-3 Recent Progress in Basic and Clinical Research of Liver Cancer Stem Cells</td>
</tr>
<tr>
<td>9:55</td>
<td>Dr. Haruhiko Takeda (Japan)</td>
<td>11-4 Genetic Alterations during Multistep Hepatocarcinogenesis Revealed by Whole Genome Sequencing</td>
</tr>
<tr>
<td>10:10</td>
<td>Dr. Gamal Shiha (Egypt)</td>
<td>11-5 Predictive Scores for Hepatocellular Carcinoma Risk Stratification after Achieving SVR Following DAAS</td>
</tr>
</tbody>
</table>

### 10:50-12:20 Session 12: HAIC, TACE, RFA, Radiation
*Chairs: Dr. Ji Dong Jia (China)/Dr. Satoshi Mochida (Japan)/Dr. Hitoshi Yoshiji (Japan)*

<table>
<thead>
<tr>
<th>Time</th>
<th>Speaker</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:50</td>
<td>Dr. Ryosuke Tateishi (Japan)</td>
<td>12-1 Radiofrequency Ablation for Hepatocellular Carcinoma</td>
</tr>
<tr>
<td>11:05</td>
<td>Dr. Shuntaro Obi (Japan)</td>
<td>12-2 Hepatic Arterial Infusion Chemotherapy (HAIC) in 2021</td>
</tr>
<tr>
<td>11:20</td>
<td>Dr. Kazuhiro Nouso (Japan)</td>
<td>12-3 Effective Use of Local Ablation Therapy for the Treatment of Early to Intermediate HCC</td>
</tr>
<tr>
<td>11:35</td>
<td>Dr. Ji Dong Jia (China)</td>
<td>12-4 The Key Recommendations by APASL PBC Guidance 2021</td>
</tr>
<tr>
<td>11:50</td>
<td>Dr. Naoki Morimoto (Japan)</td>
<td>12-5 Laparoscopic Radiofrequency Ablation in the Era of Non-viral Hepatitis</td>
</tr>
</tbody>
</table>

### Discussion Time
- 10:25-10:40
- 11:05-11:20
- 11:20-11:35
- 11:35-11:50
- 11:50-12:05
- 12:05-12:20
12:30-13:30 Luncheon Seminar (4) (Sponsored by AbbVie GK)

Chair: Dr. Masayuki Kurosaki (Japan)

Ultra-FP Treatment could be Affordable Treatment Option for Advanced Stage of HCC
Dr. Yasuteru Kondo (Japan)

Antiviral Therapy for Hepatocellular Carcinoma: Primary and tertiary Prevention
Dr. Ryosuke Tateishi (Japan)

14:30-16:00 Session 13: Intermediate-stage HCC (3) (TKI, Sorafenib, Regorafenib)

Chairs: Dr. Manoj K Sharma (India)/ Dr. Norifumi Kawada (Japan)

14:30-14:45 13-1 Exploring Tumor Microenvironment in Patients with Advanced Hepatocellular Carcinoma
Dr. Hiroaki Kanzaki (Japan)

14:45-15:00 13-2 Management Challenges for Intermediate Stage Hepatocellular Carcinoma (HCC) in the Era of Systemic Therapy
Dr. Cosmas Rinaldi A. Lesmana (Indonesia)

15:00-15:15 13-3 Impact of Skeletal Muscle Volume in Patients with Intermediate-stage Hepatocellular Carcinoma (HCC) Receiving Sorafenib: A Comparison with Advanced HCC patients
Dr. Issei Saeki (Japan)

15:15-15:30 13-4 Mechanisms and Management of Sorafenib Resistance in Hepatocellular Carcinoma
Dr. Rakhi Maiwall (India)

15:30-15:45 13-5 Optimal Sequencing of TKI after Atezolizumab and Bevacizumab in HCC
Dr. Wei-Peng Yong (Singapore)

15:45-16:00 Discussion Time

16:10-17:40 Session 14: Intermediate-stage HCC (5) (Ramucirumab, etc.)

Chairs: Dr. Pei Jer Chen (Taiwan)/ Simone Strasser (Australia)/ Dr. Namiki Izumi (Japan)

16:10-16:25 14-1 Systemic Therapy for Intermediate-stage Hepatocellular Carcinoma Including Real-world Data of Ramucirumab Treatment as Second or Later Line
Dr. Yutaka Yasui (Japan)

16:25-16:40 14-2 Analyses of Intermediate-stage Hepatocellular Carcinoma Patients Receiving TACE Prior to Designing Clinical Trials
Dr. Keisuke Koroki (Japan)

16:40-16:55 14-3 Hepatocellular Carcinoma Emergence in Armenia: Outcome of Multiple Risk Factors, January 2019 to March 2020 Nork Clinical Hospital of Infectious Diseases
Dr. Hasmik Ghazinyan (Armenia)

16:55-17:10 14-4 Management of Intermediate Hepatocellular Carcinoma - Past, Present and Future
Dr. George Lau (China)
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:10-17:25</td>
<td>14-5 <strong>Treatment Strategy of Intermediate-stage HCC: LEN-TACE Sequential Therapy</strong></td>
</tr>
<tr>
<td></td>
<td>Dr. Masatoshi Kudo (Japan)</td>
</tr>
<tr>
<td>17:25-17:40</td>
<td>Discussion Time</td>
</tr>
<tr>
<td>17:40-17:50</td>
<td><strong>Awarding Ceremony</strong></td>
</tr>
<tr>
<td>17:50-18:00</td>
<td><strong>Closing Ceremony</strong></td>
</tr>
<tr>
<td></td>
<td>Dr. Mitsuhiko Moriyama (President of APASL Oncology 2021)</td>
</tr>
</tbody>
</table>
Day 2: December 18 (Saturday) 2021
Room 2

8:00-9:00 Morning Seminar (4) (Sponsored by Takeda Pharmaceutical Co., Ltd.)
Chair: Dr. Shinichi Takahashi (Japan)
Gastric Cancer Risk with H. Pylori Infection and Gastric Cancer Management in Japan
Dr. Kazunari Murakami (Japan)

9:10-10:40 Session 15: COVID-19 in Japan
Chairs: Dr. Masashi Mizokami (Japan)/Dr. Mitsuhiko Moriyama (Japan)

9:10-9:25 15-1 Diagnosis, Genome Surveillance and Immune Response of COVID-19
Dr. Yosuke Hirotsu (Japan)

Dr. Masaya Sugiyama (Japan)

Dr. Shuichiro Shiina (Japan)

9:55-10:10 15-4 Responses to COVID-19 Outbreaks in Healthcare Setting in Japan, January 2020 - September 2021
Dr. Takuya Yamagishi (Japan)

10:10-10:25 15-5 COVID-19 in Japan
Dr. Hiroshi Yotsuyanagi (Japan)

10:25-10:40 Discussion Time

10:50-12:20 Session 16: Diagnosis of HCC
Chairs: Dr. Jee-Fu Huang (Taiwan)/Dr. Kiyoshi Hasegawa (Japan)/Dr. Masahiro Ogawa (Japan)

10:50-11:05 16-1 Imaging Evaluation of HCC in the Systemic Treatment Era
Dr. Takamichi Murakami (Japan)

11:05-11:20 16-2 Tumor Marker Profiles in Patients with Viral and Non-viral Hepatocellular Carcinoma
Dr. Hidenori Toyoda (Japan)

11:20-11:35 16-3 Diagnosis of HCC (Tentative)
Dr. Do Young Kim (Korea)

11:35-11:50 16-4 Diagnosis of Hepatocellular Carcinoma by Contrast-enhanced Ultrasound – Focusing on Early Hepatocellular Carcinoma
Dr. Hiroko Iijima (Japan)

11:50-12:05 16-5 aMAP Score Prediction of Hepatocellular Carcinoma Development in Patients with Chronic Liver Disease
Dr. Takeji Umemura (Japan)

12:05-12:20 Discussion Time
12:30-13:30 Luncheon Seminar (5) (Sponsored by Gilead Sciences K.K.)
Chair: Dr. Yoshiyuki Ueno (Japan)
Current Status of HBV Prevalence and Efforts for Eradicating Hepatic Failure by HBV Reactivation in Patients with Cancer Dr. Sachio Yoshio (Japan)
Recent Advances in Systemic Therapy for Hepatocellular Carcinoma and Management of Hepatitis B Infection Dr. Kaoru Tsuchiya (Japan)

14:30-16:00 Session 17: Intermediate-stage HCC (4) (TKI, Lenvatinib)
Chairs: Dr. Jin Mo Yang (Korea)/Dr. Kazuaki Chayama (Japan)/Dr. Takuji Torimura (Japan)

14:30-14:45 17-1 Treatment Strategy of Intermediate Stage HCC using Lenvatinib “Lenvatinib TACE Sequential Therapy”
Dr. Yusuke Kawamura (Japan)
14:45-15:00 17-2 Lenvatinib for Intermediate Stage HCC
Dr. Yoshinari Asaoka (Japan)
15:00-15:15 17-3 The Dawn of a New Era in Hepatocellular Carcinoma Treatment with Molecular Targeted Therapy and Local Therapy
Dr. Eishiro Mizukoshi (Japan)
15:15-15:30 17-4 Adjuvant Systemic Therapies in Intermediate HCC
Dr. Levent Doğanay (Turkey)
15:30-15:45 17-5 Value of Lenvatinib in the Treatment of Intermediate Stage HCC
Dr. Chun-Jen Liu (Taiwan)
15:45-16:00 Discussion Time

16:10-17:40 Session 18: Intermediate-stage HCC (6) (TKI, Lenvatinib)
Chairs: Dr. Sumiko Nagoshi (Japan)/Dr. Yoshiyuki Ueno (Japan)

16:10-16:25 18-1 Contrast-enhanced Ultrasonography for Blood Flow Detection in Hepatocellular Carcinoma During Lenvatinib Therapy
Dr. Naoki Matsumoto (Japan)
16:25-16:40 18-2 Guidelines in Evolution: Systemic Therapy for Intermediate-stage HCC
Dr. Chiun Hsu (Taiwan)
16:40-16:55 18-3 Importance of Keeping Balance Between Therapeutic Effects and Adverse Events in Lenvatinib for Hepatocellular Carcinoma～Refinement of Administration Schedule and Combination with Transarterial Therapy～
Dr. Hideki Iwamoto (Japan)
16:55-17:10 18-4 Role of Tumor Immunogenicity and Tumor-associated Macrophages in Multi-kinase Inhibitor Responses for Hepatocellular Carcinoma
Dr. Pil Soo Sung (Korea)
17:10-17:25 18-5 The Prediction Model of HBV-HCC During Anti-viral Therapy
Dr. Hong You (China)
17:25-17:40 Discussion Time
Day 2: December 18 (Saturday) 2021
Room 3

8:00-9:00  Morning Seminar (5) (Sponsored by AstraZeneca)
Chair: Dr. Hiroo Imazu (Japan)
Treatment Strategies for Acid Related Disease in Primary Care-Based on Clinical Practice Guidelines for GERD 2021
Dr. Akihito Nagahara (Japan)

9:10-10:34 Oral Free Papers (3)
Chairs: Dr. Shinya Maekawa (Japan)/Dr. Masahito Shimizu (Japan)/Dr. Katsutoshi Tokushige (Japan)

9:10-9:17 #10008  Contribution of dMMR to Accumulation of Somatic Mutations at Different Stages of HCC Development
Dr. Masayuki Ueno (Japan)

9:17-9:24 #10033  Genetic Discrimination between Multicentric Occurrence and Intrahepatic Metastasis in Multifocal HCC
Dr. Yuji Iimuro (Japan)

9:24-9:31 #10015  An Assistive Computational Tool for Defining the Segmental Anatomy of the Liver
Dr. Harvey Ho (New Zealand)

9:31-9:38 #10035  The Protective Role of DNA Methyltransferase 3B Against Inflammatory Hepatocarcinogenesis
Dr. Eriko Iguchi (Japan)

9:38-9:45 #10060  Utility of AFP, AFP-L3, and PIVKA-II for Hepatocellular Carcinoma Surveillance
Dr. Supot Nimanong (Thailand)

9:45-9:52 #10062  Natural Killer Cells Putative Role in Patients with HCV-Related Hepatocellular Carcinoma
Dr. Mohamed Abdel-Samiee (Egypt)

9:52-9:59 #10076  Let–7a and Let–7i as Biomarkers for CHC Patients with HCC Risk after Anti-viral Treatment
Dr. Ming-Lung Yu (Taiwan)

9:59-10:06 #10009  Post-treatment Cell-free DNA as a Predictive Biomarker in Systemic Therapy for HCC
Dr. Takuma Nakatsuka (Japan)

10:06-10:13 #10026  The Combination of ALBI and PT Predict Liver Dysfunction after TACE for HCC within Up-to-7 Criteria
Dr. Hiroaki Takaya (Japan)

10:13-10:20 #10063  MicroRNA Gene Polymorphisms and Development of Hepatocellular Carcinoma in Egyptian Patients
Dr. Mohamed Abdel-Samiee (Egypt)
10:20-10:27 #10079 Analysis of Sarcopenia in Patients with BCLC Stage B HCC who Received Atezolizumab Plus Bevacizumab
   Dr. Hiroaki Matsumoto (Japan)
10:27-10:34 #10080 The Simple Product of Albumin and Platelets Indicates the Stage of Liver Fibrosis and Prognosis
   Dr. Koji Fujita (Japan)

11:00-12:00 Educational Seminar (2) (Sponsored by AbbVie GK)
Chair: Dr. Junko Tanaka (Japan)

SVR & HCV-related HCC
   Dr. Yoshinari Asaoka (Japan)

HCV Eradication in the SDGs Era
   Dr. Hironao Okubo (Japan)
On-site Poster Session Program

Day 2: December 18 (Saturday) 2021 at 13:40-14:20
Room 4

On-Site Poster Session Group 1

Chair: Dr. Hirayuki Enomoto (Japan)
13:40-13:45
#10027 Hepatoma-derived Growth Factor as a Potential Therapeutic Target for Hepatocellular Carcinoma
   Dr. Hirayuki Enomoto (Japan)
13:45-13:50
#10034 Iron Chelator Deferasirox Alters Sorafenib-induced Programmed Cell Deaths of Hepatoma Cells
   Dr. Wataru Jomen (Japan)
13:50-13:55
#10052 Combination Therapy with Lenvatinib and RFA for CP A Patients with HCC Exceeding up-to-7 Criteria
   Dr. Kazushi Numata (Japan)
13:55-14:00
#10088 Examination of the Detectability of Spoke Wheel Pattern by Contrast Ultrasonography in FNH
   Dr. Masahiro Ogawa (Japan)
14:00-14:05
#10011 Bezafibrate Treatment is Associated with Reduced Risk for Development of HCC in Patients with PBC
   Dr. Atsushi Tanaka (Japan)
14:05-14:10
#10031 Safety of Atezolizumab plus Bevacizumab in Hepatocellular Carcinoma
   Dr. Hiroshi Numao (Japan)

On-site Poster Session Group 2

Chair: Dr. Fumitaka Suzuki (Japan)
13:40-13:45
#10010 Real Impact of Tumor Marker AFP and PIVKA-II in Detecting Very Small Hepatocellular Carcinoma
   Dr. Akito Nozaki (Japan)
13:45-13:50
#10054 Circulating IGFBP-1 Provides Resistance to Molecular Targeted Agent in Hepatocellular Carcinoma
   Dr. Hiroyuki Suzuki (Japan)
13:50-13:55
#10081 Relationship between Serum Kynurenine Level and Prognosis of Patients with Hepatocellular Carcinoma
   Dr. Shigemune Bekki (Japan)
13:55-14:00
#10082 Measurement of Renal Vein and IVC in Patients with Cirrhotic Ascites and Congestive Liver
   Dr. Masahiro Kaneko (Japan)
14:00-14:05
#10017 Immune Checkpoint Inhibitor as a Therapeutic Choice for Double Cancer: A Case Series
   Dr. Naoki Matsumoto (Japan)
An Autopsy Case of Ruptured Hepatocellular Carcinoma Following Administration of Lenvatinib

Dr. Kumichika Uchida (Japan)

On-site Poster Session Group 3

Chair: Dr. Ryota Masuzaki (Japan)

13:40-13:45
#10083 A Case of Mortality from an Incidental Intrahepatic Cholangiocarcinoma with Severe Cholecystitis
Dr. Yoshie Kadota (Japan)

13:50-13:55
#10041 Laparoscopic Surgery could be Most Frequently Employ as a Treatment for HCC in SVR era
Dr. Shuntaro Obi (Japan)

13:55-14:00
#10044 ATZ+BEV Therapy can Control Disease Activity in Patients Who Do Not Respond to Lenvatinib
Dr. Shuntaro Obi (Japan)

14:00-14:05
#10038 Incidence of HCC is Quite Different Depending on the History of HCC; A Prospective Study by 600 SVRs
Dr. Shuntaro Obi (Japan)

14:05-14:10
#10039 Beware of Carcinogenesis Other Than HCC; A Prospective Study by 600 SVRs
Dr. Shuntaro Obi (Japan)

14:10-14:15
#10040 Risk Factors for Occurrence of HCC after DAA Therapy; A Prospective Study by 600 SVRs
Dr. Shuntaro Obi (Japan)

14:15-14:20
#10043 Is Liver Carcinogenesis after SVR IM or MC? By Analysis of Gene Profiles
Dr. Shuntaro Obi (Japan)

On-site Poster Session Group 4

Chair: Dr. Makiko Taniai (Japan)

13:40-13:45
#10021 Major Signaling Pathway in Hepatocellular Carcinoma and Drug-matched Variants
Dr. Kenji Amemiya (Japan)

13:45-13:50
#10065 Phenotypic and Genetic Features of Multiple Nodules in HCC Based on Tumor Evolutionary Trait
Dr. Yosuke Hirotsu (Japan)

13:50-13:55
#10019 Impact of Hepatectomy for Advanced Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombus
Dr. Shohei Komatsu (Japan)

13:55-14:00
#10084 Conversion Surgery for Advanced Hepatocellular Carcinoma after Lenvatinib, a Case Report
Dr. Kazuki Kato (Japan)
14:00-14:05
#1007  TACE with Cisplatin Versus Epirubicin for Hepatocellular Carcinoma, a Randomised Controlled Trial
Dr. Osamu Aramaki (Japan)

14:05-14:10
#1070  Examination of the Effect of Embolization of Corona Enhancement Area on Local Tumor Recurrence
Dr. Yukinobu Watanabe (Japan)

On-site Poster Session Group 5
Chair: Dr. Shinpei Sato (Japan)
13:40-13:45
#10085 Experience of Antiviral Therapy in Patients Co-infected with HIV and Hepatitis Virus
Dr. Yuki Haga (Japan)

13:45-13:50
#10036 Levocarnitine Suppresses Lenvatinib-related Sarcopenia in Hepatocellular Carcinoma Patients
Dr. Hironao Okubo (Japan)

13:50-13:55
#10025 Clinical Features of Systemic Treatment in Japan
Dr. Takaaki Tanaka (Japan)

13:55-14:00
#10022 Clinical Trend of Japanese Patients with HCC in Progression of Aging Society: Clinical Role of RFA
Dr. Shota Izumi (Japan)

14:00-14:05
#10037 Two Cases of RFA for HCC in the Caudate Lobe; an Emerging Technique with Using Guided Needle Under CT
Dr. Sae Yumita (Japan)

14:05-14:10
#10030 The Cancer Risk in PSC and Ulcerative Colitis from 26 Years Retrospective Cohort Study in Japan
Dr. Takashi Taida (Japan)

On-site Poster Session Group 6
Chair: Dr. Shintaro Yamazaki (Japan)
13:40-13:45
#10053 Stereotactic Body Radiotherapy for Early-stage Hepatocellular Carcinoma: A Single-Center Experience
Dr. Shunsuke Okuyama (Japan)

13:45-13:50
#10014 Impact of Postoperative Complications on Survival of Hepatocellular Carcinoma Patients
Dr. Hisashi Nakayama (Japan)

13:50-13:55
#10028 Surgical Resection for Hepatocellular Carcinoma with Major Vascular Invasion
Dr. Shintaro Yamazaki (Japan)

13:55-14:00
#10032 Impact of Patient Age on Outcome after Resection for Hepatocellular carcinoma
Dr. Masaharu Harada (Japan)
14:00-14:05
#10056  Transient High Transaminase Elevation Does Not Affect on Short Term Outcomes after Liver Resection
        Dr. Yusuke Mitsuka (Japan)

14:05-14:10
#10003  Sex-related Differences in Predictors of HCC Incidence after DAA Therapy in Patients with HCV
        Dr. Takao Watanabe (Japan)
E-Poster Session Program

E-Poster Presentation will be available through Website of APASL Oncology 2021 at http://www.apasl-oncology2021.org/

#10001 FBL is the Hub Gene of Pulmonary Metastasis in Hepatocellular Carcinoma
Dr. Wen-Rui Wu (China)

#10002 Everolimus Protect IRI Through the Effect of Treg
Dr. Li Zhu (China)

#10013 Durability of SVR in GT3 and GT6 Patients Treated with SOF/VEL with/without RBV from China
Dr. Huagang Xiong (China)

#10016 Clinical Characteristics and Survival Analysis of Patients with HCC after HBV Negative
Dr. Hong Li (China)

#10018 Characteristics of Genomic Profile of Hepatocellular Carcinoma after Sustained Virologic Response
Dr. Hiroshi Ohyama (Japan)

#10042 A Case of Primary Biliary Cholangitis Undergoing RFA for Liver Metastasis of Cervical Cancer
Dr. Ken Nogami (Japan)

#10050 Impacts of EZH2 Inhibitor UNC1999 on Tumor and Tumor Microenvironment in Hepatocellular Carcinoma
Dr. Junjie Ao (Japan)

#10086 Regorafenib for Taiwanese Patients with Unresectable HCC after Sorafenib Failure
Dr. Ming-Lung Yu (Taiwan)

#10087 Education and information sharing method for the coming era in ablation
Dr. Maki Tobari (Japan)

#10089 MWA vs. RFA in Intermediate Stage Hepatocellular Carcinoma: A Retro-prospective Study
Dr. Diana Alcantara Babaran (Philippines)
人々のより良い健康のために。

ベーリンガーインゲルハイムは、株式を公開しない企業形態の特色を生かし、長期的な視点で、医薬品の研究開発、製造、販売を中心に事業を世界に展開している製薬企業です。

日本ベーリンガーインゲルハイム株式会社 主要製品

<table>
<thead>
<tr>
<th>薬剤名</th>
<th>剂型</th>
<th>栄養基準収載</th>
</tr>
</thead>
<tbody>
<tr>
<td>プラザキサ®カプセル</td>
<td>75mg</td>
<td>栄養基準収載</td>
</tr>
<tr>
<td>トラテンゾ®錠5mg</td>
<td>Trazenta® Tablets 5mg</td>
<td></td>
</tr>
<tr>
<td>ジャディアウン®錠10mg</td>
<td>Jardiance®</td>
<td></td>
</tr>
<tr>
<td>スピリーパ®1.25μg/2.5μgレスピマッド</td>
<td>スピリーパ®28吸入 / 60吸入</td>
<td></td>
</tr>
<tr>
<td>ジオトリブ®錠20mg</td>
<td>Spiriva® Combination Tablets AP-BP</td>
<td></td>
</tr>
<tr>
<td>オフェブ®カプセル150mg</td>
<td>Spiriva® Capsules 100mg / 150mg</td>
<td></td>
</tr>
</tbody>
</table>

※効能・効果、用法・用量、警告、禁忌を含む使用上の注意等につきましては製品添付文書をご参照下さい。
新しい細胞治療を通じて、
生活の質を高めること

皮下脂肪組織には、脂肪組織由来再生（幹）細胞（ADRC）という間質血管細胞群が含まれています。

セルーション セルセラビーキットは患者から採取した脂肪組織より細胞を分離・洗浄し、安定的に採取するための単回使用のキットです。

特徴
- 非培養
- 最適化された細胞分離工程
- 滅菌開鎖系回路
- 同一手術内完結型

セルーション セルセラビーキット
高度管理医療機器

お問い合わせ
☎ 03-6860-5700
✉ contactjp@cytori-jp.com
人々の生命を救い
人生を健やかにするために、挑みつづける。

最先端の薬品の創製。それは長く狭い道のりです。
根本的な研究開発の99%以上は失を経る不幸。
でも、笑ってあきらめない。
あなたや、あなたの大切な人の「いのち」のために。
革新的な薬とワクチンの発見、開発、提供を
私たちは続けていきます。
**Designed for 3Fr SYSTEM**

*Thinner distal segment to increase flexibility*

**Neo Cerisier SS Micro Catheter**

<table>
<thead>
<tr>
<th>Neo CerisierSS Specifications</th>
<th>Product Code</th>
<th>Description</th>
<th>Compatible Guidewire</th>
<th>JAN Code</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neo CerisierSS 110cm</td>
<td>XX0341</td>
<td>NCS-110S-SS-N</td>
<td>0.014inch</td>
<td>4560249950963</td>
</tr>
<tr>
<td>Neo CerisierSS 135cm</td>
<td>XX0342</td>
<td>NCS-135S-SS-N</td>
<td>0.014inch</td>
<td>4560249950970</td>
</tr>
</tbody>
</table>

**MEDIKIT Co., Ltd.**
13-2, Yushima, 1-chome, Bunkyo-Ku, Tokyo, 113-0034 Japan
Phone: 81-3-3839-8633 Fax: 81-3-3839-3978
URL: www.mediKit.co.jp/english/
Manufacturer
TOGO MEDIKIT Co., Ltd.
健康づくりは幸せづくり

病気になると自分で健康に治ろうとする体。

そんな健康で優しいあなたの体の声に耳を澄ませ

薬を研究・開発してきたゼリア新薬。

消化器系を中心とした医療用医薬品から

コントロールをはじめとする

コンシューマーヘルスケア事業まで。

すべての人々が健康でいきいきと生活してほしいという願いは

今、さまざまな取り組みとなって広がり続けています。
Today Astellas is working to meet unmet medical needs.

All around the world there are diseases for which no medicine has been developed. Such unmet medical needs are the battleground of Astellas. Our mission is to change tomorrow for millions of lives, one drug at a time.

Changing tomorrow

www.astellas.com/en/

製造販売元マイランEPD合同会社
東京都港区虎ノ門5丁目11番2号
（資料請求先）くすり相談室フリーダイヤル0120-938-837

2021年1月作成
Ingenia Elition 3.0T
A revolutionary breakthrough in diagnostic quality and speed

Innovation + you

ウィルソン病治療薬（鉄吸収阻害剤）・低亜鉛血症治療薬

ノベルジン®錠 25mg・50mg

ノベルジン®顆粒 5％

【効能又は効果】、「用法及び用量」、「禁忌」、「重要な基本的注意」等については、製品添付文書をご参照ください。
持続性がん疼痛治療薬
ナルサス錠
2mg 6mg
12mg 24mg

がん疼痛治療薬
ナルラピド錠
1mg 2mg
4mg

がん疼痛治療用注射剤
ナルベイン注
2mg 20mg

※「効能又は効果」、「用法及び用量」、「禁忌を含む使用上の注意」等については添付文書をご参照ください。

薬価基準収載
エンドセリン受容体拮抗薬
オプスミット錠10mg
一般名：マシテンタン／Macitentan

効能・効果、「用法・用量」、「禁忌を含む使用上の注意」等につきましては、製品添付文書をご参照ください。

製造販売元（文脈を模索・製品情報お問い合わせ先）
ヤンセンファーマ株式会社
〒101-0065 東京都千代田区西神田1-5-2
www.janssen.com/japan
www.janssenpro.jp（医薬品情報）
3D形状の太径コイルとインナーハイドロゲルで
より確実な血流抑制を追求。

AZUR® CX35
顔面型出血内薬栓用コイル

力強く、前へ
その一歩が、より良い未来の医療へ繋がると信じて。
この先の100年も、新しい医療を教えていく。
私たちはテルモです。

Stride Ahead 100th

2021年、テルモは創立100周年を迎えます。
亜鉛を自動分析装置で測定しませんか？

亜鉛（Zn）はDNAポリメラーゼを始めとする100種類以上の酵素に含まれ、タンパク質合成、ホルモン活性発現など、正常な生命維持に不可欠な微量元素です。発生・成長、組織の修復、骨の維持、生殖、感覚・食欲・免疫機能など生体内の様々な機能が亜鉛に依存されて維持されており、亜鉛欠乏の検査は疾患の治療に結びつく重要な情報の一つとなります。

亜鉛欠乏の症状：味覚・嗅覚障害、食欲低下、皮膚炎、脱毛症、創傷治癒の遅延、体力・活力低下など

アキュラスオート Zn の特長

＊ 血清、血漿および尿中の亜鉛濃度を測定できます

＊ 検体の前処理を必要としません

＊ 原子吸光法との相関が良好です

\[ y = 0.976x - 0.7 \] (n=60、血清検体)

x: 原子吸光法 y: 本品 r=0.996

<table>
<thead>
<tr>
<th>包装単位</th>
</tr>
</thead>
<tbody>
<tr>
<td>銘柄品名</td>
</tr>
<tr>
<td>---</td>
</tr>
<tr>
<td>アキュラスオート Zn</td>
</tr>
<tr>
<td>326054275</td>
</tr>
<tr>
<td>326062942</td>
</tr>
<tr>
<td>326062478</td>
</tr>
<tr>
<td>アキュラスオート Zn</td>
</tr>
<tr>
<td>326062936</td>
</tr>
</tbody>
</table>

＜別売品＞

| 品名 | 326052936 Zn標準液（300 μg/dL） | 10 mL×1 |
| 326055722 | 亜鉛コントロール（100 μg/dL） | 10 mL×1 |
| 326081127 | 亜鉛コントロール（H） | 10 mL×1 |

製造販売元 株式会社シノテスト
神奈川県相模原市南区大野台 4-1-93
https://www.shino-test.co.jp

《問い合わせ先》
株式会社シノテスト カスタマーサポート
TEL 0120-66-1141 FAX 042-753-1892

第5版 2020年12月
The Asian Pacific Association for the Study of the Liver

APASL Oncology 2022

APASL Single Topic Conference

"Liver Cancer : Clinical and Basic Research"

2022 September 1 - 3 (Thurs) - (Sat)

President
Tsutomu Masaki, MD.
Professor and Chairman,
Department of Gastroenterology and Neurology,
Faculty of Medicine, Kagawa University

Venue
Hotel Clement Takamatsu
Takamatsu-city, Kagawa, Japan

www.apaslstc-takamatsu2022.org

Scientific Secretariat
Department of Gastroenterology and Neurology,
Faculty of Medicine, Kagawa University

Congress Secretariat
APASL STC Takamatsu 2022 Congress Secretariat
c/o Academia Support Japan
Tel: +81-3-6380-0102 Fax: +81-3-6380-0103
Email: info@apaslstc-takamatsu2022.org
Nexavar® 200mg
Sorafenib Tosylate (anticancer agent / kinase inhibitor)
Deleterious / Prescription drug
Listing in the National Health Insurance drug price list
*Caution : Use under prescription from a physician, etc.

Stivarga® 40mg
Regorafenib Hydrate (anticancer agent / kinase inhibitor)
Deleterious / Prescription drug
Listing in the National Health Insurance drug price list
*Caution : Use under prescription from a physician, etc.

Please refer to the package insert for the indications, dosage and administration, and precautions including box warnings and contraindications.

Distributed and marketed by
Bayer Yakuhin, Ltd.
4-9,Umeda 2-chome
kita-ku,Osaka 530-0001,JAPAN
https://byl.bayer.co.jp/